Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Leukemia
|
February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
Gayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
JCI Insight
|
May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma
Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood Advances
|
September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Urvi A Shah, Erin Moshier, Andriy Derkach, et al.
Blood Cancer Discovery
|
September 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Santiago Thibaud, Ryan L Subaran, Scott Newman, et al.
Blood Advances
|
February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma
William A Wood, Shaji K Kumar, Emily Semmel, et al.
Blood
|
November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Neoplasia
|
June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Rudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Blood Advances
|
May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Journal of Hematology & Oncology
|
June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood Cancer Journal
|
March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium
Cindy Varga, Myra Robinson, James A Davis, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Leukemia
|
February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
Gayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
JCI Insight
|
May 5, 2026
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma
Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka, et al.
Blood Advances
|
September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Urvi A Shah, Erin Moshier, Andriy Derkach, et al.
Blood Cancer Discovery
|
September 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Santiago Thibaud, Ryan L Subaran, Scott Newman, et al.
Blood Advances
|
February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma
William A Wood, Shaji K Kumar, Emily Semmel, et al.
Blood
|
November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Neoplasia
|
June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Rudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Blood Advances
|
May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Journal of Hematology & Oncology
|
June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood Cancer Journal
|
March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium
Cindy Varga, Myra Robinson, James A Davis, et al.
Page
of 6